Caution about ketoacidosis, UTIs, and other serious ADRs with the SGLT2s

February 2016

More warnings for the SGLT2 inhibitors (Invokana, etc) will increase concerns about their safety.

These "flozins" are sometimes preferred because they have a low risk of hypoglycemia...lead to modest weight loss...and can lower BP.

Plus Jardiance (empagliflozin) has CV benefits including a reduced risk of cardiovascular death and heart failure hospitalizations.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote